Presentation is loading. Please wait.

Presentation is loading. Please wait.

MediCel Workshop Diagnostic tools and technology transfer.

Similar presentations


Presentation on theme: "MediCel Workshop Diagnostic tools and technology transfer."— Presentation transcript:

1 MediCel Workshop Diagnostic tools and technology transfer

2 The serologic in vitro diagnosis of coeliac disease is based on the following tests: tTG DPG AEA AGA In addition, recently, genetic tests have also become available on the market. In vitro diagnosis of coeliac disease Elfid 2001-2010 2

3 Available technologies can be adapted to any lab size and needs, both in terms of financial and operative resources ELISA tTG, AGA, DPG IFI AEA Dot-Blot tTG, AGA PCR HLA Technologies Elfid 2001-2010 3

4 Tissue transglutaminase is the auto-antigen responsible for AEA positivity in coeliac disease. The introduction of tTG is a milestone in the knowledge and in vitro diagnosis of CD. tTG based kits are the reference method for the in vitro diagnosis of coeliac disease Both ELISA and Rapid tests are available Tissue transglutaminase Elfid 2001-2010 4

5 ELISA tTG IgA is the reference method/test for in vitro diagnosis of coeliac disease Higher sensitivity than AEA IgG should be used in case of Total IgA deficiency mainly Kits on the market show different sensitivity and specificity values depending on the chosen antigen and/or diagnostic approach Need of instrumentation can be limited to an Elisa reader tTG - Elisa kits Elfid 2001-2010 5

6 tTG Workshop 2009 6 Elfid 2001-2010

7 tTG - Rapid test Elfid 2001-20107 Reading window Sample addition Red Latex-tTG complex Blue Latex tTG Anti-tTG Other antibodies Positive resultsNegative results

8 Rapid tests - Literature 8 Elfid 2001-2010

9 Newly introduced in the market More sensitive and specific than AGA Useful in suspected CD patients Limited use in patients with other gastrointestinal disorders Might be a complement to tTG assays in young children Useful in GFD follow-up Deamidated Gliadin Peptides Elfid 2001-2010 9

10 EB 10 Elfid 2001-2010

11 Highest specificity Sensitivity lower than tTG IFA technology normally available in all labs Raising cost of and limited availability of animal substrate HUC is an alternative Antiendomysium test Elfid 2001-201011

12 tTG autoantibodies is still the best test for CD. tTG autoantibody assays vary greatly qualitatively. IgG tTG are not as reliable as IgA in screening procedures. The introduction of DPG IgG might be helpful in some cases. Children younger than 2 yrs of age GFD follow up Total Serum IgA deficiency Both ELISA and Rapid test are available. Limited need of instrumentation. Conclusions Elfid 2001-201012

13 During the last years, many papers have been published about genetics of CD. Both HLA and non-HLA have been extensively studied. An increased number of patients is today subjected to genetic tests. Genetic tests and Coeliac Disease Elfid 2001-2010 13

14 Request of genetic tests for CD is growing up rapidly. Detection of DQ2 a/o DQ8 heterodimers only does no longer meet customers' needs. Knowledge of DR status is now a MUST and is required in medium/small centres dealing with Coeliac Disease, not only reference centres. Present Situation Elfid 2001-2010 14

15 Complete HLA status: DQ DR Identification of patients at risk. Possibility to exclude some patients before proceeding to a further testing for risk definition. What are the requirements ? Elfid 2001-2010 15

16 What we look for 16 Most common haplotypes associated to Coeliac Disease HaplotypeCoded by allelesIn linkage disequilibrium with DQ2 DQA1*05/DQB1*02DR3 DQA1*0201/DQB1*02DR7 DQ8DQA1*03/DQB1*0302DR4 DQ7DQA1*05/DQB1*0301DR11 Elfid 2001-2010

17 First Level: screening (e.g. Eu-Gen) DQ 2 and DQ8 Selection of patients requiring additional tests Second level: definition of predisposition (e.g. Eu-Gen Risk) DR (3, 4, 7, 11) and DQ (2, 8) genotypes Complete haplotypes DQB1*02 status Relative risk to develop Coeliac Disease Two level-approach Elfid 2001-2010 17

18 Inclusion/Exclusion kit 2 mixes containing specific primers for: DQA1*05, DQB1*02, DRB1*04, DQB1*0302. Positive response to any allele: indicates need of further testing Negative response: low or minimal risk. Further tests are not required First level approach Elfid 2001-201018 Mix 4DQA1*05DQB1*0302 Mix 6 DQB1*02DR4 Non DQ2/8 Mix 4DQA1*05DQB1*0302 Mix 6 DQB1*02DR4 DQ2 Mix 4DQA1*05DQB1*0302 Mix 6 DQB1*02DR4 DQ8 Mix 4DQA1*05DQB1*0302 Mix 6 DQB1*02DR4 DQ2/DQ8

19 8 mixes with specific primers providing a combined results allowing: Identification of DQ and DR genotypes Definition of complete haplotypes Definition of DQB1*02 status (homo / heterozygosis) if present Definition of relative risk for any tested patient. Second level approach Elfid 2001-201019

20 Eu-Gen Risk Elfid 2001-201020

21 Technology available Complete information about the patients status Easy interpretation of results Experienced technicians are required for proper test performance. Genetic test for Coeliac Disease Elfid 2001-201021

22 22 Elfid 2001-2010

23 CD-MEDICS Overall Objectives Development of disposable microchip for screening of coeliac disease in a portable/hand-held device carrying out multi-analyte tests Simultaneous detection of coeliac disease associated autoantibodies (DPG and tissue transglutaminase) and HLA-DQ2 and DQ8 genes. The device will have embedded communication abilities for result storage and easy follow-up, management and monitoring of the patients response to withdrawal of gluten from the diet. Elfid 2001-201023

24 2 Techniques Applied Elfid 2001-201024

25 Clinically Relevant Outcome Population based screening, and/or screening of high-risk groups and based on the data regarding HLA status, design individually tailored dietary options. Monitoring for adherence to the appropriate gluten- free diet either at their GPs office, or from their own home, with data being communicated directly to their electronic medical record. Neonatal screening in risk groups to identify newborns who may develop coeliac disease. Elfid 2001-201025

26 Features of the system Standardisation of calibrators Levels of IgA and IgG anti-tTG antibodies measured in many patient samples. To establish absolute concentrations in terms of ng/mL rather than arbitrary units. IgA and IgG anti-tTG sera of coeliac disease patients to be used as standard calibrator/controls. Clinical evaluation to see if specificity and sensitivity can be improved. Elfid 2001-201026

27 CD MEDICS instrument connectivity Elfid 2001-201027 Hospital Information System Laboratory Workstation CD MEDICS Instrument Demographics Requests/ Replies Laboratory Orders / Observations

28 Thank you for your attention


Download ppt "MediCel Workshop Diagnostic tools and technology transfer."

Similar presentations


Ads by Google